These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 29240329)

  • 21. Mycotic aneurysm of the popliteal artery as a complication of intravesical BCG therapy for superficial bladder cancer. Case report and literature review.
    Witjes JA; Vriesema JL; Brinkman K; Bootsma G; Barentsz JO
    Urol Int; 2003; 71(4):430-2. PubMed ID: 14646447
    [TBL] [Abstract][Full Text] [Related]  

  • 22. An unexpected complication of bacillus Calmette-Guérin therapy.
    Yildiz H; Colin G; Lambert M
    Acta Clin Belg; 2014 Aug; 69(4):312. PubMed ID: 24846180
    [No Abstract]   [Full Text] [Related]  

  • 23. US case of the day. Granulomatous prostatitis resulting from BCG therapy.
    Rifkin MD; Tessler FN; Tublin ME; Ross JS
    Radiographics; 1998; 18(6):1605-7. PubMed ID: 9821203
    [No Abstract]   [Full Text] [Related]  

  • 24. Epididymo-orchitis following intravesical bacillus Calmette-Guérin therapy.
    Menke JJ; Heins JR
    Ann Pharmacother; 2000 Apr; 34(4):479-82. PubMed ID: 10772435
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Miliary tuberculosis of the lung in a patient treated with bacillus Calmette-Guerin for superficial bladder cancer.
    Iantorno R; Nicolai M; Storto ML; Ciccotosto C; Cipollone G; Mastroprimiano G; Tenaglia RL
    J Urol; 1998 May; 159(5):1639-40. PubMed ID: 9554372
    [No Abstract]   [Full Text] [Related]  

  • 26. [Abdominal and retroperitoneal abscesses in a patient with bladder carcinoma receiving BCG therapy].
    Fernández JM; Cartón JA; Rodríguez A; Asensi V
    Enferm Infecc Microbiol Clin; 2009 Oct; 27(8):485-6. PubMed ID: 19406520
    [No Abstract]   [Full Text] [Related]  

  • 27. Risk-adapted use of intravesical chemotherapy.
    Lerner SP; Au JL
    BJU Int; 2008 Nov; 102(9 Pt B):1247-53. PubMed ID: 19035889
    [No Abstract]   [Full Text] [Related]  

  • 28. Long-term follow-up of intravesical bacillus Calmette-Guérin treatment for superficial transitional-cell carcinoma of the bladder involving the prostatic urethra.
    Taylor JH; Davis J; Schellhammer P
    Clin Genitourin Cancer; 2007 Sep; 5(6):386-9. PubMed ID: 17956711
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [ BCG-immunotherapy and bladder cancer].
    Rischmann P
    Prog Urol; 2008 May; 18 Suppl 5():S93. PubMed ID: 18585633
    [No Abstract]   [Full Text] [Related]  

  • 30. [Clinical investigation on the effect of intravesical instillation of antifibrinolytic agents with bacillus Calmette-Guerin on preventing bladder cancer recurrence].
    Ding GQ; Shen ZJ; Lu J; Jin XD; Chen J; Shi SF
    Zhonghua Wai Ke Za Zhi; 2005 Nov; 43(22):1457-60. PubMed ID: 16318813
    [TBL] [Abstract][Full Text] [Related]  

  • 31. BCG versus COVID-19: impact on urology.
    Desouky E
    World J Urol; 2021 Mar; 39(3):823-827. PubMed ID: 32417996
    [TBL] [Abstract][Full Text] [Related]  

  • 32. In-home Intravesical Therapy: The Future of Nonmuscle-invasive Bladder Cancer Care Delivery?
    Lyon TD; Boorjian SA; Tyson MD
    J Urol; 2023 Apr; 209(4):656-658. PubMed ID: 36637416
    [No Abstract]   [Full Text] [Related]  

  • 33. [Hematuria, dysuria, pollakiuria and general malaise, in a patient treated with BCG instillations].
    Medina Pérez M; Sánchez González M; Espino Montoro A
    Arch Esp Urol; 1998 May; 51(4):389-90. PubMed ID: 9656565
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Re: Agarwal a et al.: The safety and efficacy of different doses of bacillus Calmette Guerin in superficial bladder transitional cell carcinoma (Urology 2007;70:1075-1078).
    Agrawal MS; Bansal S
    Urology; 2009 Feb; 73(2):450-1. PubMed ID: 19185768
    [No Abstract]   [Full Text] [Related]  

  • 35. Resolution without treatment of granulomatous pneumonitis due to intravesical BCG for bladder cancer.
    Venn RM; Sharma N
    BMJ Case Rep; 2014 May; 2014():. PubMed ID: 24792029
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Mechanism of preventing the recurrence of bladder carcinoma by intravesical instillation of BCG plus IL-2].
    Wen R; Zhou G; Xie S; Lian B; Sun X; Chen J
    Zhonghua Wai Ke Za Zhi; 1998 Apr; 36(4):247-8. PubMed ID: 11825381
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cutaneous BCG of the penis after intravesical therapy for bladder cancer: a case report in a 66-year-old male.
    Hillyer S; Gulmi FA
    Can J Urol; 2009 Oct; 16(5):4866-9. PubMed ID: 19796470
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Update on the Dutch Cooperative Trial: mitomycin versus bacillus Calmette-Guérin-Tice versus bacillus Calmette-Guérin RIVM in the treatment of patients with pTA-pT1 papillary carcinoma and carcinoma in situ of the urinary bladder. Dutch South East Cooperative Urological Group.
    Witjes WP; Witjes JA; Oosterhof GO; Debruyne MJ
    Semin Urol Oncol; 1996 Feb; 14(1 Suppl 1):10-6. PubMed ID: 8727805
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Intravesical bacillus Calmette-Guérin combined with electromotive mitomycin for high-risk superficial bladder cancer.
    Bochner BH
    Nat Clin Pract Oncol; 2006 Sep; 3(9):474-5. PubMed ID: 16955082
    [No Abstract]   [Full Text] [Related]  

  • 40. [International Consensus Panel--treatment strategies for superficial bladder cancer].
    Adler S; St Niclas M
    Aktuelle Urol; 2006 Sep; 37(5):320-3; discussion 322-3. PubMed ID: 17004179
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.